Spruce Biosciences Strengthens Leadership Ahead of Key Regulatory Milestone
Event summary
- Spruce Biosciences appointed Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development on August 3, 2026.
- Dr. Cohen Pfeffer brings over a decade of experience in rare disease clinical development, including leadership roles at BioMarin Pharmaceutical.
- She was granted restricted stock units (RSUs) for 3,800 shares of Spruce’s common stock, vesting over four years.
- Spruce is advancing its lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), for Sanfilippo Syndrome Type B.
The big picture
Spruce Biosciences is bolstering its leadership team with seasoned expertise in rare disease clinical development as it approaches a critical regulatory milestone for its lead candidate, TA-ERT. The appointment of Dr. Cohen Pfeffer underscores the company's strategic focus on advancing therapies for neurological disorders with significant unmet medical needs. Her background in enzyme replacement therapies and global regulatory approvals positions Spruce to navigate the complex landscape of rare disease treatments.
What we're watching
- Regulatory Momentum
- How the appointment of Dr. Cohen Pfeffer will impact the planned biologics license application (BLA) submission for TA-ERT.
- Commercial Readiness
- Whether Spruce can leverage her experience to prepare for a potential commercial launch of TA-ERT.
- Execution Risk
- The pace at which Spruce can advance its pipeline given the strategic focus on rare neurodegenerative disorders.